Experimental immune cells take on tough tumors
NCT ID NCT06562647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early trial tests a new treatment called SY001, which uses a patient's own immune cells (macrophages) engineered to attack cancer cells that have a protein called mesothelin. The study includes just 2 people with advanced ovarian or pancreatic cancer who have not responded to prior treatments. The main goal is to check safety and find the right dose, not yet to cure the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SY001 (CAR-macrophage cells targeting mesothelin)
What this could lead to
If successful, this could point toward a new cell therapy for hard-to-treat solid tumors like advanced ovarian and pancreatic cancers.
What could go wrong
This is a very early, tiny trial (only 2 people) focused on safety and dosing. It is too small to prove effectiveness, and cell therapies can have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linyi Cancer Hospital
NOT_YET_RECRUITINGLinyi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••